Loading...
TerrAscend Corp.
TSND.TO•TSX
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.62
CA$0.06(10.71%)
TerrAscend Corp. (TSND.TO) Financial Performance & Income Statement Overview
Review TerrAscend Corp.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-3.36%
↓ 3.36%
Operating Income Growth
13.89%
↑ 13.89%
Net Income Growth
11.93%
↑ 11.93%
Operating Cash Flow Growth
38.15%
↑ 38.15%
Operating Margin
-4.89%
↓ 4.89%
Gross Margin
49.84%
↑ 49.84%
Net Profit Margin
-25.84%
↓ 25.84%
ROE
-33.38%
↓ 33.38%
ROIC
-2.75%
↓ 2.75%
TerrAscend Corp. (TSND.TO) Income Statement & Financial Overview
Review TerrAscend Corp.'s (TSND.TO) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $74.35M | $74.17M | $77.52M | $108.74M |
| Cost of Revenue | $37.02M | $37.95M | $39.84M | $59.50M |
| Gross Profit | $37.33M | $36.22M | $37.68M | $49.25M |
| Gross Profit Ratio | $0.50 | $0.49 | $0.49 | $0.45 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $26.53M | $30.05M | $28.13M | $37.77M |
| Operating Expenses | $75.58M | $33.76M | $25.06M | $37.77M |
| Total Costs & Expenses | $112.60M | $71.71M | $70.01M | $97.27M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $8.79M | $8.61M | $9.13M | $8.87M |
| Depreciation & Amortization | $5.77M | $5.74M | $5.76M | $7.71M |
| EBITDA | -$29.94M | $7.30M | $19.38M | $19.18M |
| EBITDA Ratio | -$0.40 | $0.10 | $0.25 | $0.18 |
| Operating Income | -$38.25M | $2.45M | $12.62M | $11.47M |
| Operating Income Ratio | -$0.51 | $0.03 | $0.16 | $0.11 |
| Other Income/Expenses (Net) | -$6.25M | -$9.50M | -$8.13M | -$11.25M |
| Income Before Tax | -$44.50M | -$7.05M | $4.49M | -$6.99M |
| Income Before Tax Ratio | -$0.60 | -$0.10 | $0.06 | -$0.06 |
| Income Tax Expense | -$14.34M | $14.37M | $10.73M | $13.04M |
| Net Income | -$31.85M | -$23.15M | -$8.18M | -$23.000M |
| Net Income Ratio | -$0.43 | -$0.31 | -$0.11 | -$0.21 |
| EPS | -$0.11 | -$0.08 | -$0.03 | -$0.08 |
| Diluted EPS | -$0.11 | -$0.08 | -$0.03 | -$0.08 |
| Weighted Avg Shares Outstanding | $282.09M | $272.67M | $272.67M | $290.62M |
| Weighted Avg Shares Outstanding (Diluted) | $291.50M | $291.49M | $291.49M | $290.62M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan